Log in
NASDAQ:BDTX

I-Mab Stock Forecast, Price & News

$31.51
+0.47 (+1.51 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$30.24
Now: $31.51
$31.53
50-Day Range
$26.17
MA: $31.01
$33.78
52-Week Range
$17.63
Now: $31.51
$46.25
Volume211,337 shs
Average Volume179,088 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BDTX
CUSIPN/A
CIKN/A
Phone617-252-0848
Employees30

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.44) per share

Profitability

Miscellaneous

Market Cap$1.13 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$31.51
+0.47 (+1.51 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











I-Mab (NASDAQ:BDTX) Frequently Asked Questions

How has I-Mab's stock been impacted by COVID-19?

I-Mab's stock was trading at $22.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BDTX shares have increased by 39.1% and is now trading at $31.51.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of I-Mab?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for I-Mab
.

When is I-Mab's next earnings date?

I-Mab is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for I-Mab
.

How were I-Mab's earnings last quarter?

I-Mab (NASDAQ:BDTX) released its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.03.
View I-Mab's earnings history
.

What price target have analysts set for BDTX?

5 analysts have issued twelve-month price targets for I-Mab's stock. Their forecasts range from $42.00 to $53.00. On average, they anticipate I-Mab's stock price to reach $48.00 in the next year. This suggests a possible upside of 52.3% from the stock's current price.
View analysts' price targets for I-Mab
.

Who are some of I-Mab's key competitors?

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and InVitae (NVTA).

Who are I-Mab's key executives?

I-Mab's management team includes the following people:
  • Dr. David M. Epstein, Pres, CEO & Director (Age 61)
  • Dr. Elizabeth Buck Ph.D., Exec. VP of Discovery & Translational Services (Age 45)
  • Mr. Thomas Leggett, Chief Financial Officer (Age 43)
  • Mr. Brent Hatzis-Schoch Esq., J.D., COO & Gen. Counsel (Age 55)
  • Dr. Christopher D. Roberts, Chief Scientific Officer (Age 50)

When did I-Mab IPO?

(BDTX) raised $151 million in an initial public offering on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is I-Mab's stock symbol?

I-Mab trades on the NASDAQ under the ticker symbol "BDTX."

How do I buy shares of I-Mab?

Shares of BDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is I-Mab's stock price today?

One share of BDTX stock can currently be purchased for approximately $31.51.

How big of a company is I-Mab?

I-Mab has a market capitalization of $1.13 billion. The company earns $-35,260,000.00 in net income (profit) each year or ($16.99) on an earnings per share basis. I-Mab employs 30 workers across the globe.

What is I-Mab's official website?

The official website for I-Mab is www. blackdiamondtherapeutics.com.

How can I contact I-Mab?

I-Mab's mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-252-0848 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.